SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 263 filers reported holding SAGE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 2.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $21 | -55.3% | 1 | 0.0% | 0.00% | – |
Q2 2023 | $47 | +11.9% | 1 | 0.0% | 0.00% | – |
Q1 2023 | $42 | +10.5% | 1 | 0.0% | 0.00% | – |
Q4 2022 | $38 | – | 1 | 0.0% | 0.00% | – |
Q3 2022 | $0 | – | 1 | 0.0% | 0.00% | – |
Q2 2022 | $0 | – | 1 | -93.3% | 0.00% | – |
Q1 2022 | $0 | -100.0% | 15 | -71.2% | 0.00% | – |
Q4 2021 | $2,000 | 0.0% | 52 | 0.0% | 0.00% | – |
Q3 2021 | $2,000 | +100.0% | 52 | +173.7% | 0.00% | – |
Q2 2021 | $1,000 | – | 19 | +90.0% | 0.00% | – |
Q1 2021 | $0 | -100.0% | 10 | -95.6% | 0.00% | -100.0% |
Q4 2019 | $16,000 | -48.4% | 226 | 0.0% | 0.00% | -50.0% |
Q3 2019 | $31,000 | -22.5% | 226 | 0.0% | 0.00% | -33.3% |
Q2 2019 | $40,000 | +14.3% | 226 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $35,000 | +105.9% | 226 | +25.6% | 0.00% | +50.0% |
Q4 2018 | $17,000 | -29.2% | 180 | 0.0% | 0.00% | 0.0% |
Q3 2018 | $24,000 | -11.1% | 180 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $27,000 | +237.5% | 180 | +221.4% | 0.00% | +100.0% |
Q1 2018 | $8,000 | – | 56 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 1,966,688 | $120,204,000 | 10.81% |
Integral Health Asset Management, LLC | 230,000 | $14,058,000 | 4.30% |
Asymmetry Capital Management, L.P. | 102,462 | $6,262,000 | 4.02% |
ACUTA CAPITAL PARTNERS, LLC | 225,000 | $13,752,000 | 3.74% |
DAFNA Capital Management LLC | 158,306 | $9,676,000 | 3.14% |
Bain Capital Life Sciences Investors, LLC | 499,100 | $30,505,000 | 2.84% |
Boxer Capital, LLC | 1,094,000 | $66,865,000 | 2.31% |
Palo Alto Investors LP | 590,200 | $36,073,000 | 1.98% |
Logos Global Management LP | 250,000 | $15,280,000 | 1.96% |
Bellevue Group AG | 1,579,504 | $96,539,000 | 1.33% |